These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27050625)

  • 1. Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
    Waldschmidt HV; Homan KT; Cruz-Rodríguez O; Cato MC; Waninger-Saroni J; Larimore KM; Cannavo A; Song J; Cheung JY; Kirchhoff PD; Koch WJ; Tesmer JJ; Larsen SD
    J Med Chem; 2016 Apr; 59(8):3793-807. PubMed ID: 27050625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and structure-function analysis of subfamily selective G protein-coupled receptor kinase inhibitors.
    Homan KT; Larimore KM; Elkins JM; Szklarz M; Knapp S; Tesmer JJ
    ACS Chem Biol; 2015 Jan; 10(1):310-9. PubMed ID: 25238254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilizing a structure-based docking approach to develop potent G protein-coupled receptor kinase (GRK) 2 and 5 inhibitors.
    Waldschmidt HV; Bouley R; Kirchhoff PD; Lee P; Tesmer JJG; Larsen SD
    Bioorg Med Chem Lett; 2018 May; 28(9):1507-1515. PubMed ID: 29627263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Determinants Influencing the Potency and Selectivity of Indazole-Paroxetine Hybrid G Protein-Coupled Receptor Kinase 2 Inhibitors.
    Bouley R; Waldschmidt HV; Cato MC; Cannavo A; Song J; Cheung JY; Yao XQ; Koch WJ; Larsen SD; Tesmer JJG
    Mol Pharmacol; 2017 Dec; 92(6):707-717. PubMed ID: 29070696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.
    Okawa T; Aramaki Y; Yamamoto M; Kobayashi T; Fukumoto S; Toyoda Y; Henta T; Hata A; Ikeda S; Kaneko M; Hoffman ID; Sang BC; Zou H; Kawamoto T
    J Med Chem; 2017 Aug; 60(16):6942-6990. PubMed ID: 28699740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational study of paroxetine-like inhibitors reveals new molecular insight to inhibit GRK2 with selectivity over ROCK1.
    Keretsu S; Bhujbal SP; Joo Cho S
    Sci Rep; 2019 Sep; 9(1):13053. PubMed ID: 31506468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
    Waldschmidt HV; Homan KT; Cato MC; Cruz-Rodríguez O; Cannavo A; Wilson MW; Song J; Cheung JY; Koch WJ; Tesmer JJ; Larsen SD
    J Med Chem; 2017 Apr; 60(7):3052-3069. PubMed ID: 28323425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for small molecule inhibition of G protein-coupled receptor kinases.
    Homan KT; Tesmer JJ
    ACS Chem Biol; 2015 Jan; 10(1):246-56. PubMed ID: 24984143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Paroxetine-Based GRK2 Inhibitor Reduces Internalization of the
    Bouley RA; Weinberg ZY; Waldschmidt HV; Yen YC; Larsen SD; Puthenveedu MA; Tesmer JJG
    Mol Pharmacol; 2020 Jun; 97(6):392-401. PubMed ID: 32234810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors.
    Thal DM; Yeow RY; Schoenau C; Huber J; Tesmer JJ
    Mol Pharmacol; 2011 Aug; 80(2):294-303. PubMed ID: 21596927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional analysis of g protein-coupled receptor kinase inhibition by paroxetine and a rationally designed analog.
    Homan KT; Wu E; Wilson MW; Singh P; Larsen SD; Tesmer JJ
    Mol Pharmacol; 2014 Feb; 85(2):237-48. PubMed ID: 24220010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of Highly Selective, Potent, and Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors.
    Rowlands RA; Chen Q; Bouley RA; Avramova LV; Tesmer JJG; White AD
    J Med Chem; 2021 Jan; 64(1):566-585. PubMed ID: 33393767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
    Hobson AD; Judge RA; Aguirre AL; Brown BS; Cui Y; Ding P; Dominguez E; DiGiammarino E; Egan DA; Freiberg GM; Gopalakrishnan SM; Harris CM; Honore MP; Kage KL; Kapecki NJ; Ling C; Ma J; Mack H; Mamo M; Maurus S; McRae B; Moore NS; Mueller BK; Mueller R; Namovic MT; Patel K; Pratt SD; Putman CB; Queeney KL; Sarris KK; Schaffter LM; Stoll V; Vasudevan A; Wang L; Wang L; Wirthl W; Yach K
    J Med Chem; 2018 Dec; 61(24):11074-11100. PubMed ID: 30384606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal Structure of G Protein-coupled Receptor Kinase 5 in Complex with a Rationally Designed Inhibitor.
    Homan KT; Waldschmidt HV; Glukhova A; Cannavo A; Song J; Cheung JY; Koch WJ; Larsen SD; Tesmer JJG
    J Biol Chem; 2015 Aug; 290(34):20649-20659. PubMed ID: 26032411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
    Lin H; Yamashita DS; Zeng J; Xie R; Wang W; Nidarmarthy S; Luengo JI; Rhodes N; Knick VB; Choudhry AE; Lai Z; Minthorn EA; Strum SL; Wood ER; Elkins PA; Concha NO; Heerding DA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):673-8. PubMed ID: 20006497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
    Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
    Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
    J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors.
    Carotenuto A; Cipolletta E; Gomez-Monterrey I; Sala M; Vernieri E; Limatola A; Bertamino A; Musella S; Sorriento D; Grieco P; Trimarco B; Novellino E; Iaccarino G; Campiglia P
    Eur J Med Chem; 2013 Nov; 69():384-92. PubMed ID: 24077529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.
    Xu G; Gaul MD; Liu Z; DesJarlais RL; Qi J; Wang W; Krosky D; Petrounia I; Milligan CM; Hermans A; Lu HR; Huang DZ; Xu JZ; Spurlino JC
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127602. PubMed ID: 33038544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
    Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.